Clinical Trial: DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07110038) titled 'DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma' on July 18.

Brief Summary: The DEPECA-1 trial is the first systematic Phase II trial to evaluate response and survival to a combination of antibody-drug conjugate enfortumab vedotin plus the PD-L1 inhibitor avelumab in patients with locally advanced and metastatic penile squamous cell carcinoma (PeCa) in the 1st line setting.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Penile Squamous Cell Carcinoma (PSCC)

Intervention: DRUG: Avelumab

Avelumab, 1,200 mg...